Over 2 years, bone loss did not differ from a dummy tablet; more women had hot flashes with soy isoflavones.
Trial · enrollment in the trial registry, NCT00076050 · 2 years
Levis et al., Archives of Internal Medicine, 2011
Terms and sources
- Over 2 years
- 248 women aged 45 to 60, within 5 years of menopause, at one center. A bone density T-score of −2.0 or higher was required.
- bone loss did not differ
- Spine: −2.0% with soy and −2.3% with the dummy tablet. Total hip: −1.2% and −1.4%. Femoral neck: −2.2% and −2.1%. The differences were not statistically significant.
- a dummy tablet
- The trial was double-blind.
- more women had hot flashes
- The abstract reports more "hot flashes and constipation" in the soy group. The differences were statistically significant. Vaginal cell tests, a bone marker, lipids and thyroid tests did not differ.
- soy isoflavones
- 200 mg a day in tablets. Europe PMC lists an NIH grant (NIAMS) as the funder. We could not read who supplied the tablets. An invited commentary, a letter with an author reply and a comment in another journal were published. We could not read them.
Study · Abstract only · about 2 min to read
Abstract only; about 2 minutes.
Study summary
A single-center trial enrolled 248 women within 5 years of menopause. They took 200 mg of soy isoflavones or a dummy tablet daily for 2 years. Bone density fell in both groups. At the spine it fell 2.0% with soy and 2.3% with the dummy tablet. Neither this nor the hip results differed statistically. The abstract reports more "hot flashes and constipation" in the soy group. Other outcomes did not differ. Funding: Europe PMC lists an NIH grant.
Bone loss over 3 years did not differ from a dummy tablet, except at one hip site after adjustment.
Trial · 224 in the intent-to-treat analysis · 3 years · maker-supplied
Alekel et al., American Journal of Clinical Nutrition, 2010
Terms and sources
- Bone loss over 3 years
- 255 healthy women aged 45.8 to 65 after menopause were randomized at two sites. Women with low or high bone density were excluded. They took 80 or 120 mg of soy isoflavones a day in tablets. All groups also took 500 mg of calcium and 600 IU of vitamin D3.
- did not differ
- Spine, total hip, femoral neck and whole body. This held for all women and for those who took most tablets. Bone density fell in all groups. Bone markers, endometrial thickness and adverse events did not differ either. Two more reports of this trial: endometrium and hormones did not differ; bone strength differed only in some adjusted models.
- a dummy tablet
- The trial was double-blind.
- except at one hip site after adjustment
- In women who took most tablets, the analysis was adjusted for age, body fat and a bone resorption marker. In it, 120 mg differed from the dummy tablet at the femoral neck. The authors call this a modest effect.
- maker-supplied
- Archer Daniels Midland supplied the isoflavone ingredients, NovaSoy, free of charge, per the acknowledgments. The trial was funded by NIH, per the methods. One author sits on the scientific advisory board of the Soy Nutrition Institute.
Study · Free full text · about 40 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
A trial at two sites randomized 255 healthy women after menopause. They took 80 or 120 mg of soy isoflavone tablets or a dummy tablet for 3 years. All groups also took calcium and vitamin D3. In the main analysis, bone loss at the spine, hip and whole body did not differ. After adjustment for age, body fat and a bone marker, 120 mg differed at the femoral neck. The authors call this effect modest. Funding: NIH; Archer Daniels Midland supplied the isoflavones.
Over 2 years, whole-body bone loss was smaller with 120 mg of soy germ isoflavones; regional sites did not differ.
Trial · 135, 135 and 136 randomized (results); the abstract and the registry give 403 · 2 years · maker-supplied
Wong et al., American Journal of Clinical Nutrition, 2009
Terms and sources
- Over 2 years
- 406 women aged 40 to 60, at least 12 months after their last period, at three centers. Women with low spine bone density were excluded. All took calcium and a multivitamin with vitamin D. The abstract and the registry give 403.
- smaller
- Smaller than with the dummy tablet, at 1 and 2 years, after adjustment for site, soy intake and starting values. The difference was statistically significant. The report gives it for 120 mg.
- soy germ isoflavones
- Three tablets a day. Each held 40.51 mg of isoflavones, mostly daidzein and glycitein, with 4.96 mg of genistein. The dummy tablets held cellulose.
- regional sites did not differ
- Regional bone density and mineral content, T scores and bone markers did not differ from the dummy tablet. A second report of this trial found no difference in endometrial thickness. Blood urea nitrogen rose at 2 years with isoflavones; all blood values stayed in the normal range. Two serious adverse events occurred, both in isoflavone groups. The second report calls this fewer than expected for the population.
- maker-supplied
- Frutarom Netherlands made the soy germ isoflavones, and Pharma Consulting & Industries made the tablets, per the methods. The article says the makers were not involved in design or analysis. PubMed lists an NIH grant (NCRR).
Study · Free full text · about 20 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
A multicenter trial randomized 406 women after menopause. They took 80 or 120 mg of soy germ isoflavones or a dummy tablet daily for 2 years. All took calcium and vitamin D. With 120 mg, whole-body bone loss was smaller than with the dummy tablet at 1 and 2 years. Regional bone density, mineral content and bone markers did not differ. Funding: an NIH grant; Frutarom made the isoflavones.
For a year, women ate foods with 110 mg of isoflavones or dummy foods; bone density did not differ.
Trial · as given in the abstract · 1 year · funding not stated
Brink et al., American Journal of Clinical Nutrition, 2008
Terms and sources
- women
- 237 healthy early postmenopausal women, mean age 53, at several centers. They kept their usual diet.
- foods with 110 mg of isoflavones
- Isoflavone-enriched foods, 110 mg of isoflavone aglycones a day on average. Blood and urine isoflavones rose only with these foods.
- dummy foods
- Control products, per the abstract. The trial was double-blind.
- bone density did not differ
- Spine and total body. Bone markers and hormones did not differ either, nor did safety tests and adverse events.
- funding not stated
- PubMed's record lists funding from sources other than the US government. We could not read the funding section of this paper.
Study · Abstract only · about 2 min to read
Abstract only; about 2 minutes.
Study summary
A multicenter trial gave 237 healthy women in early menopause foods enriched with isoflavones or control foods for a year. The enriched foods gave 110 mg of isoflavones a day. Blood and urine isoflavones rose only in that group. Bone density at the spine and whole body did not differ. Bone markers, hormones and safety tests did not differ either. Funding: we could not read the funding section.
For 12 weeks, moderate-to-severe hot flashes fell more with 80 mg of soy isoflavones than with a dummy tablet.
Trial · as given in the abstract · 12 weeks · funding not stated
Ferrari, Journal of Obstetrics and Gynaecology Research, 2009
Terms and sources
- moderate-to-severe hot flashes
- 180 women aged 40 to 65, without periods for at least 6 months. They had 5 or more moderate-to-severe hot flashes in the past 7 days. The trial ran at several centers.
- fell more
- At 12 weeks, daily moderate-to-severe hot flashes fell 41.2% with isoflavones and 29.3% with the dummy tablet. The difference was 1.1 a day and statistically significant, also at 6 weeks. The Kupperman index fell in both groups; the abstract gives no comparison.
- 80 mg of soy isoflavones
- One tablet a day, with 60 mg of genistein, from a soy extract. The abstract does not name the maker.
- a dummy tablet
- A matching placebo tablet. The trial was double-blind.
- funding not stated
- We could not read the funding section of this paper.
Study · Abstract only · about 2 min to read
Abstract only; about 2 minutes.
Study summary
A multicenter trial enrolled 180 women after menopause. They took one soy isoflavone tablet or a dummy tablet a day for 12 weeks. Each had at least 5 moderate-to-severe hot flashes in the week before. The tablet held 80 mg of isoflavones with 60 mg of genistein. At 12 weeks, these hot flashes fell 41.2% with isoflavones and 29.3% with the dummy tablet. The difference was statistically significant. Funding: we could not read the funding section.
Over 12 weeks, hot flashes with soy germ isoflavones differed from a dummy capsule only for both doses combined.
Trial · randomized per the abstract; the methods give 191 · 12 weeks · maker-funded
Khaodhiar et al., Menopause, 2008
Terms and sources
- Over 12 weeks
- 190 women aged 38 to 60 with 4 to 14 hot flashes a day were randomized, per the abstract. The methods give 191 women and up to 15 hot flashes. 147 completed the trial. Entry required no periods for 6 months, yet the report counts 28 completers as perimenopausal.
- hot flashes
- At 12 weeks, hot flashes fell 52% with 40 mg, 51% with 60 mg and 39% with the dummy capsule. Neither dose alone differed statistically from the dummy capsule. Both doses together did at 12 weeks, not at 8 weeks. Quality of life, hormones, thyroid tests and lipids did not differ.
- soy germ isoflavones
- 40 or 60 mg of aglycones a day in a soft-gel capsule, AglyMax. The extract came from soy germ fermented with a koji fungus; it was mostly daidzein. The report lists "gastrointestinal" side effects with the extract; two women on 60 mg stopped for them. It also says no woman reported major side effects.
- a dummy capsule
- A placebo soft-gel capsule. The trial was double-blind.
- maker-funded
- Nichimo Co., which made the extract, paid for this trial, per the article. PubMed also lists an NIH center grant.
Study · Free full text · about 21 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
A trial randomized 190 women with 4 to 14 hot flashes a day. They took 40 or 60 mg of soy germ isoflavones or a dummy capsule for 12 weeks. Hot flashes fell 52% and 51% with the two doses and 39% with the dummy capsule. Each dose alone did not differ statistically from the dummy capsule. Both doses combined did. Funding: Nichimo Co., the maker of the extract.
Over 24 weeks, hot flashes and symptom scores fell more with soy germ isoflavones than with a dummy product.
Trial · 30 per group · 24 weeks · funding not stated
Ye et al., Menopause, 2012
Terms and sources
- Over 24 weeks
- 90 Chinese women aged 45 to 60, early after menopause. The bone report of the same trial gives the entry rule: a Kupperman score above 15. Its bone report found no difference between groups, only a trend with the dose. A letter on this trial was published; we could not read it.
- hot flashes and symptom scores fell more
- Hot flashes fell 44.3% and 48.5% with 84 and 126 mg, and 27.8% with the dummy product. The Kupperman index fell 57.8% and 56.7%, and 34.6%. The differences were statistically significant.
- soy germ isoflavones
- 84 or 126 mg a day. Estradiol, the hormones FSH and LH, and blood lipids did not differ from the dummy product.
- a dummy product
- Placebo; the abstract does not describe its form. The bone report of this trial calls it single-blind.
- funding not stated
- We could not read the funding section of this paper. PubMed gives an affiliation only for the first author, a university in Guangzhou.
Study · Abstract only · about 2 min to read
Abstract only; about 2 minutes.
Study summary
A trial in Guangzhou enrolled 90 women early after menopause. They took 84 or 126 mg of soy germ isoflavones or a dummy product for 24 weeks. Hot flashes and the Kupperman symptom score fell in all groups. The falls were statistically significantly larger with both doses. Hormones and blood lipids did not differ. The bone report of this trial calls it single-blind. Funding: we could not read the funding section.
Over 10 months, hot flashes fell more with 100 mg of soy isoflavones than with a dummy product.
Trial · 40 per group · 10 months · funding not stated
Nahas et al., Maturitas, 2007
Terms and sources
- Over 10 months
- 80 women after menopause, mean age 55.1, with 5 or more hot flashes a day. Women for whom hormone therapy was ruled out were excluded.
- hot flashes fell more
- Daily hot flashes went from 9.6 to 3.1 with isoflavones and from 10.1 to 5.9 with the dummy product. The difference was statistically significant. Severity fell 69.9% and 33.7%. The Kupperman index fell in both groups.
- 100 mg of soy isoflavones
- 250 mg a day of a standardized soy extract, Glycine max AT. Endometrial thickness, mammograms, vaginal cells, lipids and hormones did not change in either group.
- a dummy product
- Placebo; the abstract does not describe its form. The trial was double-blind.
- funding not stated
- PubMed's record lists funding from sources other than the US government. We could not read the funding section of this paper.
Study · Abstract only · about 2 min to read
Abstract only; about 2 minutes.
Study summary
A trial in Brazil randomized 80 women after menopause with 5 or more hot flashes a day. They took 250 mg of a soy extract with 100 mg of isoflavones, or a dummy product, for 10 months. Daily hot flashes went from 9.6 to 3.1 with isoflavones and from 10.1 to 5.9 with the dummy product. The difference was statistically significant. Lipids, hormones and the endometrium did not change. Funding: we could not read the funding section.
Taking 60 mg of isoflavones and a dummy capsule one after the other, women's hot flashes did not differ.
Trial · Study A; Study B had 28 more women · 24 weeks · funding not stated
Campagnoli et al., Maturitas, 2005
Terms and sources
- women's hot flashes
- 29 women after menopause with more than five troublesome hot flashes a day.
- 60 mg of isoflavones
- Two capsules a day of a soy isoflavone extract. In a second trial in the same report, all women also took a fatty-acid supplement. Isoflavones again did not differ from the dummy capsule.
- a dummy capsule
- Placebo capsules. The trial was double-blind.
- one after the other
- 12 weeks of each, in random order (crossover).
- did not differ
- The isoflavone extract showed no greater effect on hot flashes than the dummy capsule.
- funding not stated
- PubMed's record lists funding from sources other than the US government. We could not read the funding section of this paper.
Study · Abstract only · about 2 min to read
Abstract only; about 2 minutes.
Study summary
A trial in Turin enrolled 29 women after menopause. They took 60 mg of soy isoflavones and a dummy capsule, one after the other, for 12 weeks each. Each had more than five troublesome hot flashes a day. Hot flashes did not differ between the two periods. A second trial in the same report added a fatty-acid supplement for all women, with the same result. Funding: we could not read the funding section.
Women took 80 mg of soy isoflavones or a dummy product for 6 months; thinking test scores did not differ.
Trial · 191 people · 6 months · funding not stated
Ho et al., Menopause, 2007
Terms and sources
- Women
- 191 Chinese women aged 55 to 76 after menopause, living in the community. 168 completed the trial.
- 80 mg of soy isoflavones
- A soy-derived isoflavone extract taken by mouth. The abstract does not name the maker.
- a dummy product
- An identical-appearing placebo. The trial was double-blind.
- thinking test scores did not differ
- Tests of memory, attention, planning, motor control, language and visual perception, and a global score. Quality of life did not differ either. Complaints were similar in both groups, mainly digestive and joint or muscle ones.
- funding not stated
- We could not read the funding section of this paper. PubMed's record lists funding from sources other than the US government.
Study · Abstract only · about 2 min to read
Abstract only; about 2 minutes.
Study summary
A trial in Hong Kong enrolled 191 women aged 55 to 76 after menopause. They took 80 mg of soy isoflavones or a dummy product daily for 6 months. Tests covered memory, attention, planning, motor control, language and visual perception. No test score differed between groups. Quality of life did not differ either. Complaints were similar in both groups. Funding: we could not read the funding section.